Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts break down its benefits and risks.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Rochelle McDonald has just been through the messiest of break-ups. “Guzman y Gomez were devastated,” she says, but 17 kilos ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is unfunded and could cost users around $500 a month.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

The TGA urged doctors to warn Ozempic users to 'be careful' and check the dose before administering it. Earlier this month, official data revealed more than 100 deaths in the United Kingdom had now ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...

Wegovy clinical trials for weight loss included 2,116 adults with overweight or obesity. Participants took 2.4 milligrams (mg) of Wegovy for up to 68 weeks (17 months), with a 7-week period ...